NanoLogix Inc. Appoints Two New Directors and Provides Operations Update
HUBBARD, Ohio, January 12th /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a biotechnology company, announces director appointments and provides operations update.
NanoLogix welcomes Daniel Barnhizer and Jeff Long to the Board of Directors. Daniel Barnhizer is an associate professor of law at Michigan State University College of Law, where he teaches and writes in the areas of business, contract, securities, and commercial law. In addition to his academic work, Professor Barnhizer also maintains an active consulting practice in corporate and securities law. Prior to joining the MSU College of Law faculty in 2001, Professor Barnhizer worked as a litigator in Washington, D.C. with the law firms of Hogan & Hartson and Cadwalader, Wickersham & Taft, where his primary practice areas focused on corporate governance, securities law, and white collar criminal law. Professor Barnhizer graduated with honors from Harvard Law School in 1995 where he was Managing Editor of the Harvard Environmental Law Review.
Jeff Long is a novelist, historian, advertising writer, and human rights advocate, He has authored eight novels, one of which was a New York Times bestseller, and two non-fiction works. He has written and developed advertising and catalogs for various companies including Overseas Adventure Travel, Lowe Alpine Systems, Thompson Safaris, and others, and is the founder of Witness Inc., a human rights and foreign aid group. Additional details about Jeff are available on www.jefflongbooks.com.
NanoLogix has secured additional square footage for the production of their BNP™ Rapid Detection kits and is awaiting financing prior to the build-out of the planned production clean-rooms and shipping/receiving area. The additional area is adjacent to the existing NanoLogix headquarters and more than doubles current company space in Hubbard, Ohio to approximately 4,000 square feet. The company also announces its intention to hold a 2009 shareholder meeting during the second quarter, with the date to be announced.
CEO Bret Barnhizer stated, “The addition of Daniel Barnhizer and Jeff Long to our Board of Directors brings two very capable people to the Company --- Daniel, for his expertise in multiple aspects of corporate and business law; and Jeff Long, for both his advertising experience, business acumen, and an outstanding ability to develop new paradigms. We look forward to their contributions to the company.” Director John Chatterton remarked: “I look forward to working with our new Board Members and having NanoLogix capitalize on both their creativity and expertise.”
Regarding the addition of space for production of BNP™ kits, Bret Barnhizer said “All of us in NanoLogix are elated at the prospects for ramping up production beyond the five-hundred per week capability of our Cincinnati facility. The Hubbard expansion should provide the capability to produce 48,000 kits per week”.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at www.nanologixinc.com.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Bret Barnhizer, CEO
Copyright 2010 NanoLogix, Inc All Rights Reserved